Published Date:2021-12-13 Original Link:https://www.onenessbio.com/en/news_detail128_1.htm No 1 Date of announcement 2021/12/12 Time of announcement 16:56:09 Subject The partial efficacy data for the Phase 2a study of FB825 in the treatment of atopic dermatitis in the U.S. have been analyzed To which item it meets paragraph 10 Date of events 2021/12/11 Statement      1.Product:FB825 anti-CεmX humanized...Read More